Multi-Specific Binding Proteins for HER2-Targeted NK Cell Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, including those for prostate, breast, and lung cancers, are often ineffective and have significant adverse side effects, and existing immunotherapies do not adequately activate natural killer cells to target cancer cells effectively.
Innovation Solution
Development of multi-specific binding proteins that bind to HER2 on cancer cells and the NKG2D and CD16 receptors on natural killer cells, activating the immune system to enhance cancer cell destruction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If multi-specific binding proteins are used to activate natural killer cells, then cytotoxicity against cancer cells is increased, but device complexity increases
Solution Approach 1:
The patent combines multiple binding specificities into a single protein molecule. The multi-specific binding protein integrates HER2 binding capability (for cancer cell targeting) and CD16 binding capability (for NK cell engagement) into one unified structure, enabling simultaneous dual-functionality without requiring separate molecules or complex cellular mechanisms
Solution Approach 2:
The binding protein is designed with multi-functional capabilities: it can bind to HER2 on cancer cells, bind to CD16 on natural killer cells, and potentially engage multiple NK cell receptors (NKG2D, NCRs). This universal design allows one protein to perform multiple therapeutic functions including target cell recognition, immune cell recruitment, and activation signaling
2Reliability
If multi-specific binding proteins target cancer cells with low HER2 expression, then therapeutic response is improved, but manufacturing precision requirements increase
Solution Approach 1:
The patent employs parameter optimization in the binding protein design, specifically tuning the affinity constants (Kd values) of different binding sites. The HER2 binding site and CD16 binding site are engineered with specific affinity ranges that allow the protein to effectively bind target cells with low HER2 expression while maintaining stability and avoiding non-specific binding
Data Source
AI summary
Multi-specific binding proteins that bind HER2, the NKG2D receptor, and CD16 are described, as well as pharmaceutical compositions and therapeutic methods useful for the treatment of cancer.